Generative AI Medical Writing Tool for the Pharmaceutical and Biotechnology Industries From TrialAssure Gets a Major Upgrade to Make Scientific Document Creation Easier

December 11, 2024

CANTON, Mich. (December 10, 2024) – TrialAssure®, a global leader in AI-enabled, human-driven solutions for the pharmaceutical industry and beyond, today announced a groundbreaking addition to its TrialAssure LINK® AI content creation and medical writing tool. The new Microsoft Word AI Assistant enables content generators, like medical writers, and other content generators across several industries, to seamlessly integrate LINK AI’s advanced large language model (LLM) functionality into the widely used MS Word application. This innovation significantly enhances the efficiency and quality of the document creation experience.

The new AI Assistant from TrialAssure was developed in response to direct industry feedback from medical writers who must work in MS Word, citing its comprehensive formatting and editing features. This update ensures that users no longer need to compromise on document quality or efficiency when using AI-powered content generating applications.

“Medical writers live and breathe Microsoft Word,” said Prasad M. Koppolu, COO, TrialAssure. “By integrating our LINK AI Assistant with the full functionality of MS Word, we’re providing writers with the best of both worlds to create complex, scientific documents faster, without sacrificing the rich functionality that they are accustomed to. At the same time, it allows companies to manage and deploy highly valuable writing subject matter experts across their portfolio in an optimal manner.”


Accelerating Document Creation in the Pharmaceutical Industry

The LINK AI medical writing tool is designed to help pharmaceutical companies meet growing resource demands and transparency compliance requirements across the drug development lifecycle. LINK® AI efficiently develops, translates, and drafts a wide range of clinical, technical, and plain language documents, such as:

  • Plain Language Summaries (PLS), PLS of clinical trial results, PLS of publications, PLS of Clinical Study Protocol, and Informed Consent Forms (ICF)
  • Clinical and technical documents, including Clinical Study Protocol, Clinical Study Report (CSR), patient safety narratives, and Statistical Analysis Plan (SAP) – built from industry standards and templates such as TransCelerate and CDISC.
  • Customizable templates, source types, and settings to produce any other document type

These drafts are created in a fraction of the time that it typically takes to write from scratch. On average, LINK AI eliminates four weeks from a six-week drafting process, ensuring faster time-to-market and enhanced efficiency for medical writing teams.


How LINK AI Works

TrialAssure LINK AI jumpstarts the writing process by digesting structured and unstructured data sources to instantly generate highly accurate document drafts based on standard or custom templates. Medical writers can refine and revise the content using intuitive prompts, modular editing tools, and AI-generated suggestions based on deep understanding of generative AI and best practices for prompt engineering.

Key features include:

  • Iterative Prompting: Refine AI-generated text effectively in an intuitive, chat-style format.
  • Text Validation: Utilize secondary AI agents to perform additional tasks, such as quality control, understandability assessment, style and formatting checks, and other customizable functions.
  • Integrated Graphics and Charts: Automatically generate visuals to complement text.

 

The LINK AI application also supports team collaboration by managing workflows, tracking internal approvals, and enabling remote teamwork—all designed to shorten timelines and reduce workload redundancies.

Early adopters have expressed enthusiasm for the AI assistant, citing its ability to streamline workflows and deliver professional-quality documents faster. “This enhancement allows us to combine AI innovation with the gold standard of document creation tools,” shared one Clinical Research Organization (CRO) partner.


To see how LINK AI can transform your medical writing process, watch the video and request a demo at https://www.trialassure.com/software/link/

 

ABOUT TRIALASSURE

TrialAssure® is an award-winning, global data transparency company with fast, affordable, and intelligent software and service solutions for the pharmaceutical industry and beyond. A leader in the use of artificial intelligence (AI) and machine learning (ML), TrialAssure built their AI Enabled, Human Driven™ software solutions to meet compliance goals through data, document, and image anonymization, development of technical and non-technical content using generative AI, compliance tracking, and more. Established in 2009, TrialAssure’s global team has a proven track record in building strong technology that adapts to ever-changing data transparency requirements and was named Data Solution of the Year in the Data Breakthrough Awards.


For more information, visit www.trialassure.com


RECENT ARTICLES

April 24, 2025
Prenuptial Patenting: Responsible Engagement with Engineering Firms
April 24, 2025
PharmOptima, a Poratge, Michigan-based preclinical contract research organization (CRO) is advancing drug discovery through its comprehensive suite of services. Specializing in in-vivo ADME/PK, ocular research, as well as regulated large and small molecule bioanalytical and ligand binding services, PharmOptima supports clients in optimizing drug development programs efficiently and effectively. With a staff averaging 11 years of industry experience and multiple individuals with advanced degrees, PharmOptima also boasts one of the most capable and engaging teams in the industry. The company collaborates with board-certified veterinary ophthalmologist Dr. Ryan Boyd, further enhancing its ocular research capabilities. PharmOptima's team of experts is dedicated to providing high-quality services to the pharmaceutical biotechnology industries. Looking ahead, PharmOptima scientists will be presenting posters at the 2025 The Association for Research in Vision and Ophthalmology (ARVO) conference, showcasing their latest research and innovations in ocular drug development. For more information visit www.pharmoptima.com .
April 24, 2025
Two bills, HB 4332 and HB 4333 were recently re-introduced that would prohibit pathogen gain-of-function (GoF) research. Given that the House is now Republican-led raises concerns for MichBio and others that the legislation might gain traction due to misinformation over biosafety and pandemic origins. MichBio opposes such broad legislative bans as they risk undermining critical scientific progress, public health preparedness, and economic innovation. GoF research has been instrumental in developing life-saving therapies and vaccines. For instance, viral vector-based gene therapies, such as Sarepta's Elevidys for Duchenne muscular dystrophy, and oncolytic virotherapies like Amgen's Imlygic for melanoma, rely on genetically modified viruses to deliver therapeutic genes or selectively destroy cancer cells. These advancements stem from GoF methodologies that enhance viral capabilities for therapeutic purposes. Moreover, GoF research has played a pivotal role in vaccine development. Examples like the AstraZeneca and Janssen COVID-19 vaccines and Merck's ERVEBO vaccine against Ebola employs a genetically modified virus to confer protection, underscore the public health benefits derived from GoF studies. ​ Contrary to concerns that GoF research operates without sufficient oversight, multiple layers of regulation are in place. Since 2017, the U.S. Department of Health and Human Services has implemented a framework to evaluate and guide funding decisions for GoF research, particularly those involving potential pandemic pathogens. This framework includes stringent safety protocols, risk assessments, and ethical reviews. ​ MichBio is most concerned that any legislative bans that broadly define and prohibit GoF research risk stifling innovation across various scientific fields. Such bans could inadvertently encompass research in virology, microbiology, molecular biology, and synthetic biology—disciplines vital for developing new therapies, sustainable agricultural practices, and environmental remediation technologies. ​ In turn, state-level bans on GoF research could have detrimental effects on local economies and academic institutions. Such a ban could impede research critical to understanding and combating diseases, leading to a loss of federal and philanthropic funding. This could hamper the growth of the Michigan's biotech and biomedical sectors. ​  MichBio advocates for a balanced approach that reinforces existing oversight mechanisms and fosters transparent, responsible research practices essential to safeguard both public health and scientific progress.